Skip to Main Content

Author Details

Michael Ohlmeyer
Atux Iskay LLC
1993
54
22
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36907775The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.J Pediatr Surg2023
37763671Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.Medicina (Kaunas)2023
36907775The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.J Pediatr Surg2023
37458534PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.Mol Oncol2023
37526463Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.Am J Respir Cell Mol Biol2023
37526463Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.Am J Respir Cell Mol Biol2023
37763671Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.Medicina (Kaunas)2023
37458534PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.Mol Oncol2023
36119978Rapid Characterization of Solid Tumors Using Resonant Sensors.ACS Omega2022
35454859Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.Cancers (Basel)2022
35963891Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells.Sci Rep2022
36119978Rapid Characterization of Solid Tumors Using Resonant Sensors.ACS Omega2022
35454859Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.Cancers (Basel)2022
35963891Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells.Sci Rep2022
34004147The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.Cell2021
34004147The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.Cell2021
34518217TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation.Proc Natl Acad Sci U S A2021
34518217TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation.Proc Natl Acad Sci U S A2021
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
32096091Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models.Neurotherapeutics2020
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
32954276Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.Brain Commun2020
32096091Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models.Neurotherapeutics2020
32954276Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.Brain Commun2020
30641028Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function.Am J Respir Crit Care Med2019
31674825Reply: Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease.Am J Respir Cell Mol Biol2019
30389701Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.Cancer Res2019
30641028Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function.Am J Respir Crit Care Med2019
31158394Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.Pharmacol Ther2019
30830869Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.JCI Insight2019
31674825Reply: Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease.Am J Respir Cell Mol Biol2019
31158394Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.Pharmacol Ther2019
30830869Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.JCI Insight2019
30389701Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.Cancer Res2019
29358171Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.Cancer Res2018
30072621Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.Molecules2018
30021885PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.Sci Transl Med2018
30011381Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.Am J Respir Cell Mol Biol2018
29358171Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.Cancer Res2018
30021885PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.Sci Transl Med2018
30072621Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.Molecules2018
30011381Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.Am J Respir Cell Mol Biol2018
28504649Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.J Clin Invest2017
28504649Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.J Clin Invest2017
28265070BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.Proc Natl Acad Sci U S A2017
28265070BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.Proc Natl Acad Sci U S A2017
26703475Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis.J Biol Chem2016
26703475Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis.J Biol Chem2016
25333622New small molecule agonists to the thyrotropin receptor.Thyroid2015
25333622New small molecule agonists to the thyrotropin receptor.Thyroid2015
  • 1 - 50 of 108

Recommended Authors

Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Wenwei Lin
St. Jude Children's Research Hospital
Career Start Year 2007
Number of shared co-authors 0
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
Anang A Shelat
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 1
Luke L Lairson
The Scripps Research Institute
Career Start Year 2003
Number of shared co-authors 0
Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 2
Gerald H Lushington
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Edward J Hennessy
Oncology R&D
Career Start Year 2002
Number of shared co-authors 3
William H Bisson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2001
Number of shared co-authors 0
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 3
Anthony B Pinkerton
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2000
Number of shared co-authors 0
William McCoull
Oncology R&D
Career Start Year 1999
Number of shared co-authors 3
Rima Al-Awar
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1999
Number of shared co-authors 0
Jian Jin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Career Start Year 1998
Number of shared co-authors 3
Stephan C Sch??rer
Institute for Data Science and Computing, University of Miami
Career Start Year 1998
Number of shared co-authors 4
Anne Marinier
Institute for Research in Immunology and Cancer
Career Start Year 1997
Number of shared co-authors 0
Jack Taunton
University of California san francisco
Career Start Year 1996
Number of shared co-authors 5
Paul J Hergenrother
University of Illinois at Urbana-Champaign
Career Start Year 1995
Number of shared co-authors 1
Rab K Prinjha
Medicines Research Centre
Career Start Year 1994
Number of shared co-authors 3
Huy Nguyen
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 0
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 1
Mark Namchuk
Blavatnik Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 0
Christopher P Austin
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 1
Timothy A Lewis
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1990
Number of shared co-authors 0
David Uehling
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1989
Number of shared co-authors 0
Antonio Macchiarulo
Department of Pharmaceutical Sciences, University of Perugia
Career Start Year 1986
Number of shared co-authors 0
Joel Morris
National Cancer Institute
Career Start Year 1986
Number of shared co-authors 0
Stuart L Schreiber
Broad Institute
Career Start Year 1985
Number of shared co-authors 5
Robert J Ardecky
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1985
Number of shared co-authors 0
Stefan Knapp
Institute of Pharmaceutical Chemistry, Goethe University
Career Start Year 1983
Number of shared co-authors 3

Collaborators

Goutham Narla
The University of Michigan Medical School ann arbor
Co-authored papers 10
Jaya Sangodkar
University of Michigan ann arbor
Co-authored papers 8
Sudeh Izadmehr
Co-authored papers 7
David B Kastrinsky
Co-authored papers 6
Neil S Dhawan
Co-authored papers 5
Nilesh Zaware
Co-authored papers 5
Matthew D Galsky
Co-authored papers 4
Mihaly Mezei
Co-authored papers 4
Kimberly McClinch
Co-authored papers 3
Rosalie C Sears
Oregon Health and Science University
Co-authored papers 3
Krister Wennerberg
University of Copenhagen
Co-authored papers 3
Caroline C Farrington
Co-authored papers 3
Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Co-authored papers 3
Analisa DiFeo
Co-authored papers 3
Daniel C McQuaid
Co-authored papers 2
Alice C Levine
Co-authored papers 2
Weijia Zhang
Co-authored papers 2
Abbey L Perl
Co-authored papers 2
Daniela Schlatzer
Co-authored papers 2
Heather M Giannini
Co-authored papers 2
Agnes Stachnik
Co-authored papers 2
Eric Yuan
Co-authored papers 2
Shen Yao
Co-authored papers 2
Rita Tohme
Co-authored papers 2
Sahar Mazhar
Co-authored papers 2
Avi Ma'ayan
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Rita A Avelar
Co-authored papers 2
Divya Hoon
Co-authored papers 2
Caitlin M O'Connor
Co-authored papers 2
Danica D Wiredja
Co-authored papers 2
Release 1.2